clazosentan

Clazosentan is a selective endothelin receptor subtype A (ET_A) antagonist developed for the prevention and treatment of cerebral vasospasm following aneurysmal subarachnoid hemorrhage (aSAH). Endothelin-1 is a potent endogenous vasoconstrictor implicated in the pathogenesis of cerebral vasospasm after subarachnoid bleeding. By blocking the ET_A receptor, clazosentan inhibits endothelin-mediated vasoconstriction and reduces the risk of delayed ischemic neurological deficits. Clinical trials have shown that clazosentan significantly reduces angiographic and clinical vasospasm-related morbidity and mortality after aSAH but does not necessarily improve overall neurological outcomes. The drug was originally developed by Actelion Pharmaceuticals and later licensed to Idorsia[2][3][4][6][8].

Brand names

Pivlaz

Other names

clazosentanRo 61-1790Ro61-1790Ro-61-1790VML 588VML588VML-588AXV-034343AXV034343AXV 034343